List view / Grid view



Biomarkers and the tumour microenvironment

7 February 2009 | By

The current cost of developing a new medicine for the treatment of human disease has been estimated at $1 to $2 billion (€750-1.5 million1,2). Given progressive increases in the cost of developing new drugs, pharmaceutical companies are facing significant pressure to streamline discovery methods and increase the translational efficiency of…

The 14th Annual Meeting of the Association of Biomolecular Resource Facilities – Application and Optimisation of Existing and Emerging Biotechnologies

7 February 2009 | By

The ABRF 2009 meeting will present the latest developments in life science technologies and the use of these technologies. Leaders in the field will give presentations including scientific sessions and technical workshops on genomics, proteomics, imaging, and other technologies such as next generation sequencing, genotyping, microarrays, real-time PCR, proteomics and…

ITC: affinity is not everything

7 February 2009 | By

During the optimisation of drug candidates, improvements in affinity and selectivity play a critical role. This task is usually accomplished by establishing accurate correlations between the affinity/selectivity of different chemical scaffolds and through chemical modifications to a selected scaffold.

Raman spectroscopic techniques for biotechnology and bioprocessing

7 February 2009 | By

Biotechnological expertise is becoming increasingly important within the pharmaceutical industry, and will play a pivotal role in the monitoring of fermentations, particularly their optimisation within the framework of Process Analytical Technologies (PAT). The ability to harness biological processes for the development of drug therapies, so called ‘biopharmaceuticals’ provides treatments that…

What the future holds for real-time PCR

10 January 2009 | By

TATAA Biocenters, located in Gothenburg, Sweden, Prague, Czech Republic, Freising outside Münich in Germany, and Sunnyvale, California1, work with leading instrument manufacturers and reagents companies in the quantitative real-time PCR (qPCR) field on new applications, making the know-how available through hands-on courses worldwide. Every year new courses are launched based…

Stem cell research and therapeutic innovation: not always a long-term perspective

10 January 2009 | By

When talking about stem cell research and its contribution to medical innovation, distinction should be made between embryonic stem cell research, believed to have almost infinite potential but with quite long-term perspectives, and adult stem cell research, which is already offering new therapeutic applications for otherwise incurable diseases. Today, adult…

Future trends for proteomics

10 January 2009 | By

The awarding of the Nobel Prize in chemistry to Fenn, Tanaka, and Wüthrich for their work on methods for the identification and structural characterisation of biomolecules has heralded the increasing importance of proteomics in biomedical and fundamental research. Today, vendors offer a variety of mass spectrometric instruments to provide a…

The changing role of automation in High Throughput Screening

10 January 2009 | By

Among the challenges for the pharmaceutical industry, declining research productivity and increasing research costs take a prominent position. This is often put in the context of efforts in the pharmaceutical industry to automate and "industrialise" research activities, combinatorial chemistry and High Throughput Screening being the most prominent examples. An argument…

PAT Initiative review 2008

10 January 2009 | By Martin Warman, Director, MWC Ltd

As the industry approaches the five year anniversary of the ground breaking regulator initiatives (the ‘PAT framework' and ‘cGMPs for the 21st Century'1,2), it is time to assess the impact they have had on the industry and to look forward to what the industry may look like in another five…

Detecting microRNA targets or siRNA off-targets using expression data

3 December 2008 | By

Recently, small RNAs such as microRNAs (miRNAs) have been demonstrated to be important regulators in both plants and animals. In animals miRNAs act as translational repressors of target genes through a combination of inhibition of translation and mRNA destabilisation. These molecules have been implicated in a multitude of diseases, including…

European PROSPECTS for proteomics and systems biology

3 December 2008 | By

In its Research Framework Programme 7 (2007-2013), the European Commission sets the focus in health research on bringing the huge high-throughput data collection efforts of earlier programmes to the systems level. The ultimate goal of systems biology is the integration of various types of experimental data into models that represent…